Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP trimmed its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTFree Report) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,941,859 shares of the biotechnology company’s stock after selling 252,137 shares during the period. Westfield Capital Management Co. LP owned approximately 4.37% of Rocket Pharmaceuticals worth $118,138,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Annandale Capital LLC acquired a new position in shares of Rocket Pharmaceuticals in the 3rd quarter valued at $66,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Rocket Pharmaceuticals by 14.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,145 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 633 shares during the period. Amalgamated Bank lifted its stake in shares of Rocket Pharmaceuticals by 5.4% in the 4th quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock valued at $259,000 after purchasing an additional 440 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Rocket Pharmaceuticals by 7.9% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,477 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 981 shares during the period. Finally, Harbour Capital Advisors LLC acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at $282,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Price Performance

RCKT stock traded down $0.30 during mid-day trading on Friday, hitting $21.42. 584,227 shares of the company were exchanged, compared to its average volume of 589,497. Rocket Pharmaceuticals, Inc. has a 12-month low of $14.89 and a 12-month high of $32.53. The company has a current ratio of 10.47, a quick ratio of 10.47 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $24.21 and a 200-day simple moving average of $26.11.

Rocket Pharmaceuticals (NASDAQ:RCKTGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.01. During the same quarter last year, the firm posted ($0.73) EPS. As a group, equities research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.85 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on RCKT shares. StockNews.com upgraded shares of Rocket Pharmaceuticals to a “sell” rating in a research note on Friday, February 9th. JPMorgan Chase & Co. reduced their price objective on shares of Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, February 27th. UBS Group reduced their price objective on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group initiated coverage on shares of Rocket Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “neutral” rating and a $39.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $52.13.

Get Our Latest Stock Analysis on Rocket Pharmaceuticals

Insider Transactions at Rocket Pharmaceuticals

In other news, Director David P. Southwell sold 10,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $24.05, for a total transaction of $240,500.00. Following the sale, the director now owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director David P. Southwell sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $24.05, for a total value of $240,500.00. Following the sale, the director now owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David P. Southwell sold 70,000 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $24.36, for a total transaction of $1,705,200.00. Following the completion of the sale, the director now directly owns 95,160 shares in the company, valued at approximately $2,318,097.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 395,872 shares of company stock valued at $10,830,243. 31.10% of the stock is currently owned by corporate insiders.

Rocket Pharmaceuticals Company Profile

(Free Report)

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Featured Articles

Institutional Ownership by Quarter for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.